Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
GIMEMA LAL2317
Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia
- NCT03367299 ↗
- Completed
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Focused
We haven't built an HCP commentary report on GIMEMA LAL2317 (blinatumomab plus chemotherapy in adult Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on GIMEMA LAL2317 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 7 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- National Treatment Program With Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Philadelphia Chromosome-Negative B-Cell Precursor Adult Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Acute Lymphoid Leukemia; Philadelphia Chromosome-Negative B-Cell Precursor
- Interventions
- Chemotherapy + Blinatumomab
- Arms
- Chemotherapy + Blinatumomab · Experimental
- Enrollment
- 149
- Primary outcomes
- Number of patients that obtain a negative Minimal Residual Disease (MRD)
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Start
- Jun 8, 2018
- Primary completion
- Sep 2, 2024
- Results posted
- No
- Registry record
- NCT03367299 · updated Jan 22, 2025
Publications
linked from the registry- Bassan R, Chiaretti S, Della Starza I, Santoro A, Spinelli O, Tosi M, Elia L, Cardinali D, De Propris MS, Piccini M, Lussana F, Annunziata M, Chiusolo P, Zappasodi P, Borlenghi E, Leoncin M, Califano C, Bocchia M, Di Raimondo F, Grimaldi F, Tiribelli M, Candoni A, Lico A, Audisio E, Lunghi M, Mianulli AM, Di Trani M, Arena V, Messina M, Piciocchi A, Fazi P, Rambaldi A, Foa R. Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study. Blood. 2025 May 22;145(21):2447-2459. doi: 10.1182/blood.2024027500. PubMed 40009490